Evaluation of Tumor Immunity in Patients with Ovarian Cancer after Immunoscintigraphy in a Long-Term Follow-up

Background. Ovarian cancer is the ninth most common cancer among women and causes more deaths than any other type of female reproductive cancer. Albumin-bound paclitaxel is known to increase intratumoral concentration of the paclitaxel by a receptor-mediated transport process across the endothelial cell wall, thereby breaching the blood/tumor interface. We present below three cases in which nab-paclitaxel based chemotherapy has been used in different settings for patients with ovarian cancer.Case Presentation. In the first case nab-paclitaxel was used along with carboplatin in adjuvant setting, in the second case, nab-paclitaxel was used along with carboplatin and bevacizumab as second line chemotherapy in a relapsed ovarian cancer case, and the third case delineates the use of nab-paclitaxel along with cisplatin as third line chemotherapy.Conclusion. In all the three scenarios, patients tolerated the chemotherapy well, as well as responding well to nab-paclitaxel based chemotherapy. The patients are currently on long-term follow-up and have been having an uneventful postchemotherapy.

Download Full-text

Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON1)

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.5509 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 5509-5509 ◽

Cited By ~ 15

Author(s):

A. C. Swart

Keyword(s):

Ovarian Cancer ◽

High Risk ◽

Adjuvant Chemotherapy ◽

Adjuvant Treatment ◽

Early Stage ◽

Risk Groups ◽

P Value ◽

Long Term Follow Up

5509 Background: ICON1 and a meta-analysis of all relevant trials demonstrated an improvement in 5 year recurrence-free and overall survival (RFS and OS) for women with early-stage epithelial ovarian cancer (ES EOC) treated with adjuvant chemotherapy compared to no adjuvant chemotherapy. We aimed to determine if this initial benefit is maintained long-term and whether benefit is different with different risk groups of patients defined by stage, grade and histology. Method: 477 women with ES EOC were recruited from centres in Italy (271 women) UK (195) Switzerland (11) between August 1991 and January 2000. 5-year results were presented at ASCO 2001. Systematic long-term follow up was planned and completed in May 2006. Results: With a median follow-up of 9.2 years, 168 women have developed recurrent disease or died and 144 women have died. The Hazard Ratio (HR) for RFS of 0.70 in favour of adjuvant chemotherapy (95% CI 0.52–0.95 p= 0.023) translated into an improvement of 10-year absolute RFS of 10% from 57 to 67%. For OS, HR was 0.74 (95% CI 0.53–1.02 p= 0.066), a corresponding improvement in 10-year absolute OS of 8% from 64% to 72%. 26% of patients died from causes other than ovarian cancer. Stage I patients were grouped as low (Ia, grade 1), medium (Ia grade 2, Ib or Ic grade 1) and high risk (Ia, grade 3, Ib or IC grade 2 or 3, any clear cell). The test of interaction between risk groups and adjuvant treatment for RFS and OS was 0.055 and 0.13, respectively. The HR, 95%CI and p value are summarised in the table . Conclusions The long-term benefit of adjuvant treatment on RFS is confirmed. There is clear evidence that adjuvant chemotherapy reduces the risk of recurrence/death or death alone in high-risk patients but not in the low-risk group. [Table: see text] [Table: see text]

Download Full-text

Long term follow-up after laparoscopic management of invasive ovarian cancer

The Journal of the American Association of Gynecologic Laparoscopists ◽

10.1016/s1074-3804(03)80029-4 ◽

2003 ◽

Vol 10 (3) ◽

pp. S10

Author(s):

M Canis ◽

G Mage

Keyword(s):

Ovarian Cancer ◽

Laparoscopic Management ◽

Long Term Follow Up

Download Full-text

Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

International Journal of Gynecological Cancer ◽

10.1136/ijgc-00009577-200311001-00003 ◽

2003 ◽

Vol 13 (Suppl 2) ◽

pp. 144-148 ◽

Cited By ~ 8

Author(s):

M. J. Piccart ◽

K. Bertelsen ◽

G. Stuart ◽

J. Cassidy ◽

C. Mangioni ◽

...

Keyword(s):

Ovarian Cancer ◽

Randomized Clinical Trials ◽

Advanced Ovarian Cancer ◽

Progression Free Survival ◽

Clinical Response Rate ◽

Free Survival ◽

Long Term Follow Up ◽

Clinically Significant

Two independent and consecutive randomized clinical trials, conducted by the American Gynecological Oncology Group and by an European–Canadian Intergroup, have shown superiority, in clinical response rate, progression-free survival, and overall survival, of a cisplatin–paclitaxel regimen over cisplatin–cyclophosphamide given as first-line chemotherapy for women with advanced epithelial ovarian cancer. The results of these studies, published with a median follow-up of about 3 years, have been updated with a 6.5-year follow-up: In each case, an 11% absolute gain in survival favoring the paclitaxel arm is shown; this advantage remains both statistically and clinically significant and supports a role for paclitaxel in frontline chemotherapy for advanced ovarian cancer.

Download Full-text

Intraperitoneal Alpha-emitting Radio Immunotherapy with Astatine-211 in Relapsed Ovarian Cancer; Long-term Follow-up with Individual Absorbed Dose Estimations

Journal of Medical Imaging and Radiation Sciences ◽

10.1016/j.jmir.2019.11.082 ◽

2019 ◽

Vol 50 (4) ◽

pp. S94

Author(s):

Andreas Hallqvist ◽

Per Albertsson ◽

Ragnar Hultborn ◽

Stig Palm ◽

Karin Bergmark ◽

...

Keyword(s):

Ovarian Cancer ◽

Absorbed Dose ◽

Long Term Follow Up

Download Full-text

Long-Term Follow-Up after Surgical Management for Atypical Endometriosis: A Series of Nine Cases

Case Reports in Oncology ◽

10.1159/000496178 ◽

2019 ◽

Vol 12 (1) ◽

pp. 76-83 ◽

Cited By ~ 1

Author(s):

Yasuhito Tanase ◽

Ryuji Kawaguchi ◽

Tomoko Uchiyama ◽

Hiroshi Kobayashi

Keyword(s):

Ovarian Cancer ◽

Clinical Characteristics ◽

Median Overall Survival ◽

Case Series ◽

Endometrioid Carcinoma ◽

Long Term Follow Up ◽

Laparoscopic Cystectomy ◽

Atypical Endometriosis

Background and Objective: Atypical endometriosis is reported to possess a precancerous potential attributed to premalignant changes characterized by cytological atypia and architecture proliferation. Although the coexistence of atypical endometriosis and neoplasms has been reported, cases of atypical endometriosis transformation to carcinoma are rarely reported. The purpose of this case series was to evaluate the prognosis of atypical endometriosis. Subjects and Methods: Data from nine women who underwent surgical treatment including cystectomy and salpingo-oophorectomy with or without hysterectomy and diagnosed with atypical endometriosis was analyzed. Between January 2006 and January 2018, the clinical characteristics and prognosis of atypical endometriosis were evaluated. Results: During the follow-up period, eight of nine patients with atypical endometriosis did not develop malignant epithelial tumors, although one patient developed endometrioid carcinoma, grade 1, 48 months after her right laparoscopic cystectomy. The median overall survival period for all patients was 68 (range 13–131) months. Conclusion: When we encounter the cases of atypical endometriosis, it is necessary to consider the possibility of ovarian cancer and carefully follow those cases for long periods.

Download Full-text